1-9 of 9
Ignacio Garrido-Laguna
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration

Gregory L. Beatty, Devora Delman, Jiayi Yu, Mingen Liu, Joey H. Li, Liti Zhang, Jae W. Lee, Renee B. Chang, Nathan Bahary, Eugene P. Kennedy, Andrea Wang-Gillam, Gabriela R. Rossi, Ignacio Garrido-Laguna
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3514–3525.
https://doi.org/10.1158/1078-0432.CCR-23-0535
Published: 01 September 2023
View article titled, Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
Open the PDF for Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration in another window
Includes: Supplementary data
Journal Articles

Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC

Vaia Florou, Andrew Elliott, Matthew H. Bailey, David Stone, Kajsa Affolter, Heloisa P. Soares, Chris Nevala-Plagemann, Courtney Scaife, Phillip Walker, W. Michael Korn, Emil Lou, Rachna T. Shroff, Peter J. Hosein, Ignacio Garrido-Laguna
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3408–3417.
https://doi.org/10.1158/1078-0432.CCR-22-3724
Published: 01 September 2023
View article titled, Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC
Open the PDF for Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC in another window
Includes: Supplementary data
Journal Articles

A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors

Niharika B. Mettu, Susanna V. Ulahannan, Johanna C. Bendell, Ignacio Garrido-Laguna, John H. Strickler, Kathleen N. Moore, Robert Stagg, Ann M. Kapoun, Leonardo Faoro, Sunil Sharma
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 882–892.
https://doi.org/10.1158/1078-0432.CCR-21-2780
Published: 03 March 2022
View article titled, A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors
Open the PDF for A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

E. Gabriela Chiorean, Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia Jalikis, Michael J. Pishvaian, Jordan Berlin, Marcus S. Noel, Jennifer M. Suga, Ignacio Garrido-Laguna, Dana Backlund Cardin, Marc R. Radke, Mai Duong, Shay Bellasea, Andrew M. Lowy, Howard S. Hochster
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (23): 6314–6322.
https://doi.org/10.1158/1078-0432.CCR-21-1789
Published: 01 December 2021
View article titled, Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513
Open the PDF for Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513 in another window
Includes: Supplementary data
Journal Articles

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Filip Janku, Haeseong Park, S. Greg Call, Kiran Madwani, Yasuhiro Oki, Vivek Subbiah, David S. Hong, Aung Naing, Vivianne M. Velez-Bravo, Tamara G. Barnes, Fredrick B. Hagemeister, Gerald S. Falchook, Daniel D. Karp, Jennifer J. Wheler, Sarina A. Piha-Paul, Ignacio Garrido-Laguna, Elizabeth J. Shpall, Luis E. Fayad, Sattva S. Neelapu, Funda Meric-Bernstam, Razelle Kurzrock, Michelle A. Fanale
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (21): 5579–5587.
https://doi.org/10.1158/1078-0432.CCR-20-1215
Published: 02 November 2020
View article titled, Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Open the PDF for Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

Activity of the T-type calcium channel antagonist Mibefradil in pancreatic cancer xenografts

Ignacio Garrido-Laguna, Aik Choon Tan, Maria Cristina Villarroel, N.V. Rajeshkumar, Belen Rubio-Viqueira, Lloyd Gray, Manuel Hidalgo
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (19_Supplement): B49.
Published: 15 August 2014
View article titled, Activity of the T-type calcium channel antagonist Mibefradil in pancreatic cancer xenografts
Journal Articles

Developing a novel method for predicting tumor responses to drug combination based on pathway expression signatures

Maria Villarroel, Aik Choon Tan, Ignacio Garrido-Laguna, Belen Rubio-Viqueira, N.V RajeshKummar, Antonio Jimeno, Manuel Hidalgo
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (19_Supplement): B51.
Published: 15 August 2014
View article titled, Developing a novel method for predicting tumor responses to drug combination based on pathway expression signatures
Journal Articles

Tumor Engraftment in Nude Mice and Enrichment in Stroma- Related Gene Pathways Predict Poor Survival and Resistance to Gemcitabine in Patients with Pancreatic Cancer

Ignacio Garrido-Laguna, Maria Uson, N.V. Rajeshkumar, Aik Choon Tan, Elizabeth de Oliveira, Collins Karikari, Maria C. Villaroel, Ana Salomon, Gretchen Taylor, Rajni Sharma, Ralph H. Hruban, Anirban Maitra, Daniel Laheru, Belén Rubio-Viqueira, Antonio Jimeno, Manuel Hidalgo
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (17): 5793–5800.
https://doi.org/10.1158/1078-0432.CCR-11-0341
Published: 01 September 2011
View article titled, Tumor Engraftment in Nude Mice and Enrichment in Stroma- Related Gene Pathways Predict Poor Survival and Resistance to Gemcitabine in Patients with Pancreatic Cancer
Open the PDF for Tumor Engraftment in Nude Mice and Enrichment in Stroma- Related Gene Pathways Predict Poor Survival and Resistance to Gemcitabine in Patients with Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Patients with Advanced Head and Neck Cancers Have Similar Progression-Free Survival on Phase I Trials and Their Last Food and Drug Administration–Approved Treatment

Ignacio Garrido-Laguna, Filip Janku, Gerald S. Falchook, Siqing Fu, David S. Hong, Aung Naing, Joanne Aaron, Xuemei Wang, Merrill Kies, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (15): 4031–4037.
https://doi.org/10.1158/1078-0432.CCR-10-0672
Published: 28 July 2010
View article titled, Patients with Advanced Head and Neck Cancers Have Similar Progression-Free Survival on Phase I Trials and Their Last Food and Drug Administration–Approved Treatment
Open the PDF for Patients with Advanced Head and Neck Cancers Have Similar Progression-Free Survival on Phase I Trials and Their Last Food and Drug Administration–Approved Treatment in another window
Includes: Supplementary data